The Food and Drug Administration’s Vaccines and Related Biological Products Advisory Committee recommended that adults over the age of 18, who have already received an initial dose of Johnson & Johnson (JNJ) - Get Johnson & Johnson (JNJ) Report and Janssen’s COVID vaccine, receive a second dose of the vaccine two months after initial inoculation.
Many members of the FDA panel said the Johnson & Johnson vaccine should be considered a two-dose vaccine much like the vaccines offered by Pfizer (PFE) - Get Pfizer Inc. Report and Moderna (MRNA) - Get Moderna, Inc. Report.
Johnson & Johnson submitted data showing that a second dose, administered two months after the initial dose, boosted protection against symptomatic infection from 72% to 94%.
If the FDA agrees with the recommendation, it will move to the CDC and director Dr. Rochelle Walensky for final approval. The second doses would be available immediately upon approval.